The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients

Diabetes Research and Clinical Practice

Volumn 124, Issue , 2017, Pages 1-10

  Smits, Mark M ^a   Tonneijck, Lennart ^a   Muskiet, Marcel H A ^a   Hoekstra, Trynke ^a,b   Kramer, Mark H H ^a   Diamant, Michaela ^a   van Raalte, Daniël H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Exenatide; GLP 1 receptor agonist; Haemodynamics; Heart rate; Liraglutide; Sympathetic nervous system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; LIRAGLUTIDE; METFORMIN; PLACEBO; SITAGLIPTIN; TOLBUTAMIDE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ADRENERGIC SYSTEM; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR PARAMETERS; CAUCASIAN; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HEART HEMODYNAMICS; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSCILLOMETRY; PHOTOELECTRIC PLETHYSMOGRAPHY; POLLAKISURIA; POSTMENOPAUSE; POSTPRANDIAL STATE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TONOMETRY; VASCULAR RESISTANCE; AGED; BLOOD; BLOOD PRESSURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; HEART RATE; HEMODYNAMICS; METABOLISM; MIDDLE AGED; OVERWEIGHT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEART RATE; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; OVERWEIGHT; PEPTIDES; PLACEBOS; POSTPRANDIAL PERIOD; SITAGLIPTIN PHOSPHATE; VASCULAR RESISTANCE; VENOMS;

EID: 85009061052     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.12.011     Document Type: Article

References (31)

1. [1] Trahair, L.G., Horowitz, M., Jones, K.L., Postprandial hypotension: a systematic review. J Am Med Dir Assoc 15 (2014), 394–409, 10.1016/j.jamda.2014.01.011.
2. [2] Aronow, W.S., Ahn, C., Association of postprandial hypotension with incidence of falls, syncope, coronary events, stroke, and total mortality at 29-month follow-up in 499 older nursing home residents. J Am Geriatr Soc 45 (1997), 1051–1053.
3. [3] Smits, M.M., Muskiet, M.H.A., Tushuizen, M.E., Kwa, K.A.A., Karemaker, J.M., van Raalte, D.H., et al. Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase. Diabetes Res Clin Pract 106 (2014), 617–626, 10.1016/j.diabres.2014.09.044.
4. [4] Holst, J.J., The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007), 1409–1439, 10.1152/physrev.00034.2006.
5. [5] van Genugten, R.E., Möller-Goede, D.L., van Raalte, D.H., Diamant, M., Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes Obes Metab 15 (2013), 593–606, 10.1111/dom.12050.
6. [6] Trahair, L.G., Horowitz, M., Stevens, J.E., Feinle-Bisset, C., Standfield, S., Piscitelli, D., et al. Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia 58 (2015), 1769–1778, 10.1007/s00125-015-3638-0.
7. [7] Jang, A.L., Hwang, S.K., Kim, D.U., Effects of guar gum ingestion on postprandial blood pressure in older adults. J Nutr Health Aging 19 (2015), 299–304, 10.1007/s12603-015-0453-8.
8. [8] Trahair, L.G., Horowitz, M., Hausken, T., Feinle-Bisset, C., Rayner, C.K., Jones, K.L., Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, mesenteric blood flow and glycemic responses to intraduodenal glucose in healthy older subjects. J Clin Endocrinol Metab 99 (2014), E2628–E2634, 10.1210/jc.2014-2475.
9. [9] Yonenaga, A., Ota, H., Honda, M., Koshiyama, D., Yagi, T., Hanaoka, Y., et al. Marked improvement of elderly postprandial hypotension by dipeptidyl peptidase IV inhibitor. Geriatr Gerontol Int 13 (2013), 227–229, 10.1111/j.1447-0594.2012.00903.x.
10. [10] Smits, M.M., Muskiet, M.H.A., Tonneijck, L., Hoekstra, T., Kramer, M.H.H., Diamant, M., et al. Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. Br J Clin Pharmacol 81 (2016), 613–620, 10.1111/bcp.12843.
11. [11] Mendis, B., Simpson, E., MacDonald, I., Mansell, P., Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 74 (2012), 437–444, 10.1111/j.1365-2125.2012.04214.x.
12. [12] Smits, M.M., Tonneijck, L., Muskiet, M.H.A., Hoekstra, T., Kramer, M.H.H., Pieters, I.C., et al. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open, 5, 2015, e009579, 10.1136/bmjopen-2015-009579.
13. [13] Fehse, F., Trautmann, M., Holst, J.J., Halseth, A.E., Nanayakkara, N., Nielsen, L.L., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90 (2005), 5991–5997, 10.1210/jc.2005-1093.
14. [14] Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93 (1996), 1043–1065.
15. [15] Qiao, W., Li, J., Li, Y., Qian, D., Chen, L., Wei, X., et al. Acarbose, the α-glucosidase inhibitor, attenuates the blood pressure and splanchnic blood flow responses to meal in elderly patients with postprandial hypotension concomitant with abnormal glucose metabolism. Blood Press Monit 21 (2016), 38–42, 10.1097/MBP.0000000000000160.
16. [16] Ramanathan, T., Skinner, H., Coronary blood flow. Contin Educ Anaesthesia Crit Care Pain 5 (2005), 61–64, 10.1093/bjaceaccp/mki012.
17. [17] Buckberg, G.D., Fixler, D.E., Archie, J.P., Hoffman, J.I., Experimental subendocardial ischemia in dogs with normal coronary arteries. Circ Res 30 (1972), 67–81.
18. [18] Schultz, M.G., Abhayaratna, W.P., Marwick, T.H., Sharman, J.E., Myocardial perfusion and the J curve association between diastolic blood pressure and mortality. Am J Hypertens 26 (2013), 557–566, 10.1093/ajh/hps077.
19. [19] Rajkumar, C., Simpson, H., Jennings, G.L., Dart, A.M., Postprandial silent ischaemia following a fatty meal in patients with recently diagnosed coronary artery disease. J Hum Hypertens 14 (2000), 391–394.
20. [20] Ussher, J.R., Drucker, D.J., Cardiovascular actions of incretin-based therapies. Circ Res 114 (2014), 1788–1803, 10.1161/CIRCRESAHA.114.301958.
21. [21] Unger, J.R., Parkin, C.G., Glucagon-like peptide-1 (GLP-1) receptor agonists: differentiating the new medications. Diabetes Ther 2 (2011), 29–39, 10.1007/s13300-010-0013-5.
22. [22] Smits, M.M., van Raalte, D.H., Tonneijck, L., Muskiet, M.H.A., Kramer, M.H.H., Cahen, D.L., GLP-1 based therapies: clinical implications for gastroenterologists. Gut 65 (2016), 702–711, 10.1136/gutjnl-2015-310572.
23. [23] Smits, M.M., Tonneijck, L., Muskiet, M.H.A., Kramer, M.H.H., Cahen, D.L., van Raalte, D.H., Gastrointestinal actions of GLP-1 based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab 18 (2016), 178–185, 10.1111/dom.12593.
24. [24] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F.E., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322, 10.1056/NEJMoa1603827.
25. [25] Robinson, L.E., Holt, T.A., Rees, K., Randeva, H.S., O'Hare, J.P., Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open, 3, 2013, 10.1136/bmjopen-2012-001986 e001986–e001986.
26. [26] Nakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., et al. Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care 39 (2016), e22–e23, 10.2337/dc15-1437.
27. [27] Jensen, M.T., Suadicani, P., Hein, H.O., Gyntelberg, F., Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart 99 (2013), 882–887, 10.1136/heartjnl-2012-303375.
28. [28] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326, 10.1056/NEJMoa1307684.
29. [29] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242, 10.1056/NEJMoa1501352.
30. [30] Röhrborn, D., Wronkowitz, N., Eckel, J., DPP4 in diabetes. Front Immunol, 6, 2015, 386, 10.3389/fimmu.2015.00386.
31. [31] Bogert, L.W.J., Wesseling, K.H., Schraa, O., Van Lieshout, E.J., de Mol, B.A.J.M., van Goudoever, J., et al. Pulse contour cardiac output derived from non-invasive arterial pressure in cardiovascular disease. Anaesthesia 65 (2010), 1119–1125, 10.1111/j.1365-2044.2010.06511.x.